Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15821538 | 0.84 | KEAP1 (0.33) | KEAP1CA1CA2HDAC1HDAC6 | |
| SCHEMBL15820509 | 0.82 | THRB (0.40) | KEAP1RXFP1THRBPKMHDAC1 | |
| SCHEMBL2203971 | 0.79 | KEAP1 (0.44) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL11991561 | 0.79 | CES2 (0.38) | KDM4EKMT2AMEN1ASPHKDM8 | |
| SCHEMBL16155018 | 0.78 | CFTR (0.42) | KDM4EKMT2AMEN1MAPTGLA | |
| SCHEMBL24752830 | 0.78 | KEAP1 (0.42) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL3574434 | 0.78 | DPP4 (0.47) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL2621717 | 0.76 | KDM4E (0.37) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL1571198 | 0.76 | KDM4E (0.41) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL30186857 | 0.76 | KDM4E (0.41) | KEAP1KDM4EKMT2AGFERRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161908-B1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | ANNJI PHARM CO LTD (TW) | 2026-04-01 | — | — | EP | disclosed |
| US-20230212129-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2023-07-06 | — | — | US | disclosed |
| US-20230212129-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2023-07-06 | — | — | US | disclosed |
| US-20230212129-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2023-07-06 | — | — | US | disclosed |
| EP-4161908-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2023-04-12 | — | — | EP | disclosed |
| CN-115843292-A | Quinazoline derivatives as selective HDAC6 inhibitors | 安基生技新药股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021252475-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252475-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-12-16 | — | — | WO | disclosed |
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-1699421-B1 | Lactate salts of quinolinone compounds and their pharmaceutical use | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1650203-B1 | Process of preparation of benzimidazol-2-yl quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212129-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC5 | KEAP1 52/4885KDM4E 2459/4885KMT2A 1430/4885 |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | KEAP1 709/4885KDM4E 4563/4885KMT2A 3742/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | KEAP1 3176/4885KDM4E 3069/4885KMT2A 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.